MannKind 10-Q: Q3 Revenue Up 24% to $101.9M, Net Loss Widens to $23.2M
MNKD sits 70% above its 52-week low of $2.23.
Summary
MannKind's Q3 revenue rose 24% to $101.9 million on doubled product sales, but SG&A more than doubled and the net loss widened to $23.2 million, leaving $96.6 million in cash and investments against a $325 million term loan.
Key Events · Earnings and Guidance · MNKD
-
Q3 Revenue Up 24% to $101.9M
Total revenues rose to $101.9 million from $82.1 million a year ago, with commercial product sales doubling to $45.0 million and royalties up 12% to $37.5 million.
-
Net Loss Widens to $23.2M
The quarter swung to a $23.2 million net loss, or $0.07 per share, from $8.0 million of net income a year earlier, as SG&A jumped 111% to $61.4 million on Furoscix promotion and ReadyFlow launch costs.
-
Cash Falls to $96.6M
Cash, cash equivalents and investments totaled $96.6 million at September 30, 2026, down from $177.4 million at December 31, 2025, after $58.3 million of operating cash use in the first nine months.
-
Debt Load Weighs on Results
Interest expense reached $27.0 million for nine months on the $325.0 million Blackstone term loan, which carries a 9.18% effective rate and matures August 6, 2030.
Analysis · MNKD · Life Sciences
Revenue growth is real — commercial product sales doubled to $45.0 million on Furoscix and Afrezza — but the cost of building that franchise is outrunning it. SG&A jumped 111% to $61.4 million in the quarter and $173.8 million for nine months, pushing the company to a $23.2 million quarterly loss from a $8.0 million profit a year ago. The balance sheet is the pressure point: cash, equivalents and investments fell to $96.6 million from $177.4 million at year-end, and operations consumed $58.3 million of cash in nine months versus generating $26.2 million a year earlier. Against a $325.0 million Blackstone term loan at a 9.18% effective rate, the company is now dependent on continued revenue ramp and access to capital. The July private placement's $49.8 million net proceeds went straight out the door to fund the $44.8 million CVR payment triggered by the Furoscix ReadyFlow approval.
How filings like this one have moved
In the 30 days to Nov 8, 2026, 36.3% of the 2976 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNKD was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.